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INTRODUCTION:  Liver  angiosarcoma  is  a  very  uncommon  tumour  of mesenchymal  origin,  representing
between  0.1–2%  of  all primary  tumours  of the  liver,  affecting  mainly  men  in  their sixth  or seventh  decade
of  life,  with  a high  mortality  in  the  ﬁrst  years  (Chaudhary  et al.,  2015).  Literature  reports  of  its  surgical
treatment  vary  from  a total  or  partial  hepatectomy  with or without  liver  transplant.
PRESENTATION  OF  CASE:  A 37 year old  male,  with  a 7 year  history  of  a fatty  liver,  was  found  to have a 12 cm
diameter  tumour  in  a  cirrhotic  liver,  during  an  abdominal  Computed  Tomography  (CT)  scan.  Patient  was
asymptomatic  with  negative  tumour  markers,  yet  tumour  liver  biopsy  revealed  a  Liver Angiosarcoma
with  positive  immunohistochemistry  for neoplastic  cells  CD31  and  CD34.
Patient  was deemed  candidate  for a partial  hepatectomy  of the  affected  liver segments  which  was
done  without  complications  and  no evidence  of other  tumour  lesions  was  found  during  surgery.  Patient
continued  oncologic  management  with  ongoing  chemotherapy.
DISCUSION:  Liver  Angiosarcoma,  although  rare, persists  with a high  mortality  due  to  its  aggressive  nature.
Never the  less  liver  transplantation,  although  proven  to  be an  effective  treatment  for  many  pathologies
that  culminate  in liver  failure,  fails to improve  patients’  survival  and  prognosis,  when  compared  to partial
hepatectomy  as surgical  management  to  for liver  Angiosarcoma,
CONCLUSION:  Partial  hepatectomy  as surgical  management,  followed  by adjuvant  therapy,  for  Liver
Angiosarcoma  continues  to prove  favourable  results  and  prognosis  compared  to Liver  Transplantation.
© 2016  The  Authors.  Published  by  Elsevier  Ltd  on  behalf  of  IJS Publishing  Group  Ltd.  This is  an  open
he  CCaccess  article  under  t
. Introduction
Primary tumours of the liver are divided into two  groups:
pithelial and non-epithelial. Tumours of epithelial origin include
epatocellular carcinoma, cholangiocarcinoma, hepatoblastoma
nd ﬁbrolamellar hepatocellular carcinoma variant. Tumours of
on-epithelial origin include the hepatic angiosarcoma, rhab-
omyosarcoma, hemangioendothelioma and lymphoma [2]. The
epatic angiosarcoma is a tumour of mesenchymal origin, repre-
enting 0.1–2% of all primary tumours of the liver and generally
ppearing during the sixth or seventh decade of life [1]. Given the
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rasplantes, Universidad ICESI, Cali, Colombia.
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G.J. Echeverri).
ttp://dx.doi.org/10.1016/j.ijscr.2016.09.044
210-2612/© 2016 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing G
reativecommons.org/licenses/by-nc-nd/4.0/). BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
infrequent nature of this pathology, we decided to publish this case
report with emphasis on a review of the literature and the surgical
management of the tumour.
2. Presentation of case
Male patient, 37 years old, with a 7-year history of a fatty liver
who during a CT scan, was  found to have a 12 cm mass in segment II
and III of the liver (Figs. 1–3) and two  satellites in the right lobe, of
1 cm and 2 mm in segment VII and V respectively, associated with
a cirrhotic liver (Child-Pugh A).
The patient was asymptomatic with negative tumour markers
and an alpha-fetoprotein of 1.7 mg/dL. He was therefore referred
to our institution for possible surgical and medical management,
with the possibility of a liver transplantation (LT). The Hepatobiliary
Surgery Group and the Transplantation Surgery Group evaluated
roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. Axial views of a contrast enhanced CT scan of the liver revealing a large
heterogenous tumour in the second and third segment of the liver, as signaled by
the red arrows.
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lig. 2. Coronal views of a contrast enhanced CT scan of the liver revealing a large
umour in the second and third segment of the liver.
he patient in November 2015 during which a liver biopsy, guided
y laparoscopy, was carried out.
During the surgery, a cirrhotic liver was observed with a hyper-
ascular mass in segments II and III of the left lobe. The liver biopsy
as taken using Trucut, with no complications, and the ﬁnal report
howed a liver angiosarcoma with immuno-histochemistry posi-
ive for neoplastic cells CD31, CD34 and with p53-Vimentin greater
han 90% and an index of cell proliferation (DAO) with Ki67 of 50%
Fig. 4).
It was decided, by the Board of Transplantation Surgery, Hep-
tology and Oncology, that the patient was a candidate for a left
epatectomy and later adjuvant medical treatment with radiofre-
uency and chemotherapy for the management of the satellite
esions.Fig. 3. Sagital views of a contrast enhanced CT scan of the liver revealing a large
tumour in the second and third segment of the liver.
The patient was taken to open surgery where a cirrhotic, micro-
nodular liver was found, without ascites, with a vascular type
tumour that occupied segments II, III and IV of the liver (Fig. 5).
No tumour lesions were found on the right side, neither peritoneal
planting, nor in the rest of the abdominal cavity. A left Hepatectomy
was performed with cholecystectomy, with no complications, and
the patient was moved to the intensive care unit for post-surgery
medical management, where they remained for one week.
During his clinical evolution, the patient presented with
hyperbilirubinemia, raised transaminase and ascites, which were
medically managed without the patient presenting any clinical
signs of post-surgery acute liver failure.
The patient had no inﬂammatory response, tolerated oral med-
ication and experienced decreasing ascites and liver enzymes. He
was discharged after two  weeks of hospitalisation upon a normal
physical examination. Laboratory controls, via outpatient consul-
tations, were normal.
Three weeks after his discharge, the patient showed evi-
dence of a satisfactory clinical evolution, being asymptomatic
with a normal physical examination: Heart Rate = 82/min, Blood
Pressure = 110/70 without ascites, without jaundice, Aspartate
Aminotransferase = 25, Alanine Aminotransferase = 28, alkaline
phosphatase 189 and Gamma-Glutamyl Transpeptidase = 227.
8 month after the surgery the patient continues receiving adyu-
vant chemotherapy with favourable results.
3. Discussion
Liver Angiosarcoma may  manifest as a single mass with satel-
lite nodules or as a diffuse inﬁltrative mass throughout the liver
tissue due to the atypical proliferation of endothelial cells in the
hepatic sinusoids [3]. Creating a high mortality rate due to haem-
orrhages (secondary to tumour rupture) or acute liver failure with
a 2 years survival rate of 3% [4]. Seventy ﬁve percent of the cases
are of unknown aetiology [5], however, several risk factors have
been accused, such as exposure to vinyl chloride, chronic intake of
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Fig. 4. Panel A (40× H&E Stain), B (100× H&E Stain) and C (400× H&E Stain) shows a le
alternating with areas of hemorrhage and necrosis. Panel D (400× CD31) shows Immuno
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Finally, in 2015 a retrospective series was  performed in Taiwan,
of 3503 patients with primary tumours of the liver. Thirteen hadFig. 5. Left lobe showing the cirrhotic tumour mass in Segments II and II.
rsenic, anabolic steroids, androgens, cyclophosphamide and the
se of oral contraceptives [6,7].
The majority of patients present with non-speciﬁc symptoms
ut usually start with pain in the right hypochondrium, ascites
nd hepatomegaly. As shown in our case report, up to 12.5% of
ases are found in asymptomatic patients, with the tumour in the
iver parenchyma usually being found incidentally and then liver
ngiosarcoma being conﬁrmed via histological ﬁndings in a liver
iopsy [1,8].
LT has become the gold standard therapeutic modality for the
ultiple pathologies that contribute to a terminal liver disease. Its
se as a therapeutic management tool for primary or metastatic
epatic malignancies is, however, controversial [9].
Initial treatment consists of performing resection at the
natomic site of the affected liver. In many cases, however, tak-
ng in consideration the inﬁltrative behaviour of the tumour, the
resence of regional metastases and the distances between thesesion composed of fusiform cells with pleomorphic nuclei lining the sinusoids and
histochemistry showing neoplastic cells positive to monoclonal antibody CD31.
satellites, it is not possible to perform a resection [1,10]. LT was,
therefore, suggested as a potential better solution.
In 1990 Starzl and collaborators from the University of Pitts-
burgh published one of the ﬁrst retrospective studies involving LT
and malignant tumours, which reported a series of 1469 patients
who received LT between 1980 and 1988. 115 of these patients
received a LT due to malignancy. Two patients due to a Liver
Angiosarcoma with 100% mortality in the ﬁrst year and a high recur-
rence of the disease in the ﬁrst three months after the LT [11]. In
2006, a retrospective series of 19 patients with a variety of pri-
mary sarcomas and metastatic tumours, which all received LT, was
published. There were 6 cases of angiosarcoma and 13 cases of
metastatic sarcoma; survival at 12 months was 20% with a 100%
mortality at 15 months after LT [9].
Later, in 2013, the European Register of Liver Transplants pub-
lished a retrospective study of 22 cases with liver angiosarcoma
who received LT between 1983 and 2004, which where compared
with 108 cases of patients that received LT due to Hemangioendote-
lioma. For patients with liver angiosarcoma, survival at 12 months
was 24%, with mortality at 24 months of 100%; for patients with
hemangioendothelioma, survival at 12 months was  87% [12]. This
led to the conclusion that patients with liver angiosarcoma did not
beneﬁt from the LT. For this reason, after being evaluated by the
Transplant Group, our patient was  treated via a partial hepatec-
tomy.
In 2014, a case report of a 5 years old female patient diagnosed
with liver angiosarcoma was published in the Journal Paediatric
Transplantation. She received a LT along with post-transplant man-
agement with Sirolimus. There was  no recurrence of the disease
until the 27th month, argued to be due to mTOR inhibitors regulat-
ing proliferation, differentiation and cell migration and generating
an anti-neoplastic effect [13]. This case reintroduced LT as a thera-
peutic option in conjunction with adjuvant therapy.Liver angiosarcoma and received surgical management plus treat-
ment with chemotherapy. This study showed a greater survival
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ate, over 2 years: from 32 to 69 months in total [14]. Suggesting,
s well as recent evidence, that liver Angiosarcoma must be treated
ggressively with liver resection in order to improve patient’s prog-
osis [15].
In our case report, given the high recurrence and high mortality
n LT patients and the promising results using neoadjuvant ther-
py to increase the survival of patients, we decided to carry out
 partial surgical resection of the affected liver parenchyma along
ith chemotherapy, demonstrating promising results in a rare and
ggressive liver disease.
. Conclusion
Liver Angiosarcoma is a rare tumour with a poor long-term prog-
osis due to massive haemorrhages and its high recurrence rate.
ence partial hepatectomy of the affected liver tissue with adyu-
ant therapy has been recognized to improve patients’ survival
hen compared to liver transplant.
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